Product NDC: | 0074-3956 |
Proprietary Name: | Kaletra |
Non Proprietary Name: | Lopinavir and Ritonavir |
Active Ingredient(s): | 80; 20 mg/mL; mg/mL & nbsp; Lopinavir and Ritonavir |
Administration Route(s): | ORAL |
Dosage Form(s): | SOLUTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 0074-3956 |
Labeler Name: | AbbVie Inc. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | NDA021251 |
Marketing Category: | NDA |
Start Marketing Date: | 20100618 |
Package NDC: | 0074-3956-46 |
Package Description: | 160 mL in 1 BOTTLE (0074-3956-46) |
NDC Code | 0074-3956-46 |
Proprietary Name | Kaletra |
Package Description | 160 mL in 1 BOTTLE (0074-3956-46) |
Product NDC | 0074-3956 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | Lopinavir and Ritonavir |
Dosage Form Name | SOLUTION |
Route Name | ORAL |
Start Marketing Date | 20100618 |
Marketing Category Name | NDA |
Labeler Name | AbbVie Inc. |
Substance Name | LOPINAVIR; RITONAVIR |
Strength Number | 80; 20 |
Strength Unit | mg/mL; mg/mL |
Pharmaceutical Classes | HIV Protease Inhibitors [MoA],Protease Inhibitor [EPC],HIV Protease Inhibitors [MoA],Protease Inhibitor [EPC] |